The Schistosomiasis Control Initiative at Imperial College London (SCI) is a charitable institution (HMRC reference number: X2361).
In 2002 the Bill and Melinda Gates Foundation’s Global Health Programme granted a £20 million award to establish the SCI at Imperial College London. The award was directed at delivering treatment for schistosomiasis and intestinal worms to millions of sub-Saharan Africans at high risk of serious disease.
By 2006, the SCI was a founding partner of the Global Network for Neglected Tropical Disease Control (GNNTDC) and expanded its remit to integrating the control or elimination of seven NTDs.
By 2007, the SCI has facilitated delivery of approximately 40 million treatments of praziquantel against schistosomiasis, and many more deworming doses of albendazole.
In 2010, SCI begain managment of ICOSA - a programme funded by the Department for International Development (DFID) - which will deliver 203 million treatments against schistosomiasis and intestinal helminths in 10 countries in sub Saharan Africa by December 2018.
In April 2013, SCI announced that the organisation had facilitated delivery of its 100 millionth treatment of praziquantel against schistosomiasis. Now in 2016, we have helped more countries establish national control programmes, and several other countries implement smaller pilot projects and treated over 60 million people last year for schistosomiasis and soil-transmitted helminths.
SCI continue to grow to meet the need, but with over 230 million people still needing regular treatment there remains a long road ahead to control and then to eliminate schistosomiasis.